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Two yeast genes, ARDI and NAT], are required for the
expression of an N-terminal protein acetyltransferase.
This activity is required for full repression of the silent
mating type locus HML, for sporulation, and for entry
into Go. While the NAT] gene product is thought to be
the catalytic subunit of the enzyme, the role of the ARD1
protein has remained unclear. We have used epitope
tagged derivatives of ARD1 and NAT1 to provide
biochemical evidence for the formation of an
ARDi -NATi complex, and to show that both proteins
are required for the N-terminal acetyltransferase activity.
We also present evidence for the formation of
ARDl-ARD1 homodimers. Deletion analysis suggests
that the C-terminal region of ARD1 may be involved in
the formation of both ARD1-ARDI and ARD1 -NAT1
complexes.
Key words: protein modification/protein-protein inter-
actions/yeast
Introduction
The ARD] and NAT] genes of Saccharomyces cerevisiae are
required for the expression of an N-terminal protein
acetyltransferase activity (Lee et al., 1989a; Mullen et al.,
1989; Park and Szostak, 1990). Loss of this acetyltransferase
due to mutation of either of these genes results in several
phenotypes, including an a-specific mating defect-the
consequence of derepression of the silent mating type locus
HMLa, a defect in sporulation and a loss of viability in
stationary phase (Whiteway and Szostak, 1985; Whiteway
et al., 1987; Mullen et al., 1989; Lee et al., 1989a).
The NAT] gene product is likely to be the catalytic
component of the N-terminal acetyltransferase. Purification
of the enzyme from yeast appeared to yield a single
polypeptide (Lee et al., 1988) with the molecular weight
predicted for the NATI protein. In addition, the NATI
protein contains sequence similarities to the chloramphenicol
acetyltransferase (CAT) gene product (Mullen et al., 1989).
The role of the ARDI protein in N-terminal protein
acetyltransferase activity, however, has remained unclear.
The ARD] gene product could in principle be required either
for NAT] expression or activity. The possibility that ARD1
might be a transcriptional activator of NAT] was initially
supported by two aspects of its sequence-the presence of
a stretch of acidic amino acids similar to that found in many
yeast activators (Ma and Ptashne, 1987) and a region of weak
sequence similarity to the homeobox domain of MATa2
Oxford University Press
(Whiteway and Szostak, 1985). The fact that purification
of the enzyme led to the isolation of NAT1 alone also
supported this possibility. The alternative, that ARDI is a
regulatory or catalytic component of the enzyme itself, is
supported by the observations of Mullen et al. (1989) who
showed that the NAT] gene is expressed in ardl mutant cells
and that both gene products must be overexpressed in order
to obtain elevated enzyme activity.
We present in this report biochemical evidence showing
that the ARDI protein is an essential subunit of the N-
terminal protein acetyltransferase complex.
Results
ARD1 functions after NAT1 transcription
In order to examine the role of ARDI in NAT] function,
we transferred an ADHI::NAT] promoter fusion in a
multicopy plasmid (pJM124, a gift from R.Sternglanz;
Mullen et al., 1989) into an ardl mutant strain (9-2B) and
examined the phenotype of the resulting strain. Despite the
fact that the ADHJ::NATI construct produces NATI mRNA
in large excess over that produced in wild-type cells (data
not shown), the strain showed the typical ardl mutant
phenotypes of a-specific sterility and inability to sporulate.
This result shows that the lack of N-terminal acetyltransferase
activity in ardl mutants is not due to inefficient NAT]
transcription and that the ARDI gene product is required at
some post-transcriptional step for the formation of N-terminal
acetyltransferase activity.
ARD 1 forms a complex with NAT1
Since both ARD] and NAT] are required for the expression
of N-terminal acetyltransferase activity in vivo (Mullen et al.,
1989; Park and Szostak, 1990), and since the overexpression
of both genes is required for the overproduction of the
enzyme (Mullen et al., 1989), it is possible that both ARD1
and NAT1 are subunits of the enzyme. In order to test this
possibility directly, we constructed a set of strains that
overproduce epitope tagged versions of ARDI, NATI or
both (Figure 1), and analyzed them by immunoprecipitation
using antibodies that recognize the epitope tags. We marked
the ARD1 protein with an epitope, derived from c-myc, that
can be recognized by a monoclonal antibody (Evans et al.,
1985). The anti-myc antibody specifically immunoprecipit-
ates the ARDmyc fusion protein (compare lanes a and e,
Figure 2A). The same antibody immunoprecipitates an
additional protein from extracts prepared from cells
overexpressing both ARDmyc and untagged wild-type NATI
(Figure 2A, lane b). The extra protein is the same size as
the NAT1 protein, suggesting that the ARDmyc protein
forms a complex with NAT1.
To confirm the physical interaction between the ARDI
and NAT1 proteins, we repeated the immunoprecipitation
using an epitope tagged form of NAT1. For this purpose,
we marked NAT1 with an epitope derived from the
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samples prior to loading onto gradients. Fractions 10- 14 from the bottom
of the gradient were assayed for catalase and fractions 15 -22 for aldolase,
following instructions provided by the manufacturer. Every fraction was
subjected to immunoprecipit tion using anti-myc antibody as described above.
N-terminal acetyltransferase assay
The enzyme assay was carried out on immunoprecipitates as described (Lee
et al., 1988) with minor modifications. We only assayed immunoprecipitates
since crude extracts contain other acetyltranferase activities and non-specific
hydrolases that interfere with the assay. An assay mixture contains the
enzyme (immunoprecipitate), 20 jiM ACTH (1-24) and 6.8 1M [3H]acetylCoA (3.18 Ci/mmol, Amersham) in 75 mM Tris pH 8.2, 150 mM NaCl,
0.1 mM EDTA and 2 mM ,3-mercaptoethanol. The assay mixture was
incubated for 1 h at room temperature. The enzyme activities were measured
by counting the amount of radioactivity present in ACTH after collecting
th substrate on glass fiber filters.
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the N-terminal acetyltransferase activity seen in the NATI
dimer preparation may actually be due to the presence of
a small amount of ARDi -NAT1 complex.
The idea that ARD1 is a necessary component of the
acetyltransferase is supported by our observation thatimmunoprecipitates obtained from cells overexpressing bothNATmyc and ARDI contain readily detectable enzymeactivity, while immunoprecipitates obtained from cellsoverexpressing only NATmyc do not contain detectable
enzyme activity. The possibility that ARD1 functions tomodify the substrate specificity of NAT1 is not supportedby our experiments with several peptide substrates: theARD1 -NAT1 complex appears to have a qualitatively
similar substrate specificity (unpublished results) to thatreported for the NAT1 dimer (Lee et al., 1988).
The weak sequence similarity of part of the ARD1 protein
to the homeodomain (Whiteway and Szostak, 1985) isprobably not significant. Deletion of a part of this regiondecreases but does not abolish ARDI function. This region
of the ARD1 protein lacks a crucial tryptophan residue foundin all other homeodomains examined so far (Burglin, 1988).
We have presented both genetic and biochemical evidencefor self-association of ARDI. Purification of N-terminal
acetyltransferase activity led to the isolation of dimeric NAT1protein (Lee et al., 1988). Therefore, it is possible that in
the absence of the other subunit, both ARD1 and NAT1 exist
as homodimers. On the other hand, our experiments
demonstrate that N-terminal acetyltransferase activity is a
property of the ARD1-NAT1 complex. If this species is
a heterodimer, it must form in competition with the formation
of the two homodimers. This view is consistent with the fact
that the C-terminal region of the ARD1 protein is requiredfor interaction with both NAT1 and ARD1. Slow exchange
of subunits between homo- and heterodimers would explain
our low recovery of enzyme activity in reconstitutionexperiments involving the mixing of extracts containingoverexpressed ARDI and NAT1.It is suprising that although the ARD1-NAT1 N-terminalacetyltransferase is responsible for the acetylation of a largenumber of proteins (Mullen et al., 1989; Lee et al., 1989b),only a few very specific phenotypes are observed in ardl
or nati mutants. It is likely that the N-terminal acetylationof most proteins is not of great importance, and that onlyin a few critical cases is N-terminal acetylationphysiologically significant. For example, we have shown thatacetylation of the N-terminal serine of histone H4 (Park andSzostak, 1990) or histone H2B (unpublished data) is notrequired, since the N-terminal amino acid can be replacedwithout loss of function by a variety of other amino acidsthat are not acetylated.Further studies on the ARD1-NAT1 N-terminal
acetyltransferase and in particular the identification andcharacterization of the substrates responsible for the ardl
and nati phenotypes will be necessary to unravel the in vivofunctions of N-terminal acetylation.
Materials and methods
Yeast strains and media
The genotypes and sources of S. cerevisiae used in this work are as follows:M107-8B, MATa his3 leu2 ura3 trpl can] ardl::HIS3 (M.Whiteway);M107-6C, MATai his3 leu2 ura3 can] (M.Whiteway); 9-2B, MATa his3leu2 ura3 can] ardl::URA3 (M.Whiteway); 9-3C, MATa his3 leu2 ura3can] (M.Whiteway); W303-la, MATa his3 leu2 ura3 canl(R.Sternglanz);
and AMR7, MATa his3 leu2 ura3 cani natl::URRA3 (R.Sternglanz). SDcontained 0.67% Difco yeast nitrogen base without amino acids, 2% glucose,
and amino acids essential for auxotrophic strains as described by Sherman
et al. (1981). SD-galactose was the same as SD except that galactose was
added instead of glucose.
Plasmids
The chimeric proteins used in this study are diagrammed in Figure 1. Wild-
type ARDI protein and all of the following hybrid proteins wereoverexpressed by placing the corresponding gene under the control of theDEDI promoter (Hope and Struhl, 1986) on a multicopy plasmid. The
lexA-ARD fusion protein was made by fusing the DNA binding domainof lexA (amino acids 1-87, encoded by a HindIII-Xmnnl fragment ofplasmid pRB480 (provided by R.Brent) in frame to the entire ARDI coding
sequence. The related ARD25 protein consists of the same lexA DNAbinding domain fused to seven amino acids (PTLEDPH) derived from a
polylinker sequence, followed by a C-terminal fragment of ARDI (amino
acids 166-238). ARD34 is similar to ARD25 except that the last 11 amino
acids of ARDI (amino acids 228-238) were replaced by a c-myc epitope(DMEQKLISEEDLN) derived from the plasmid pUCmyc (provided byB.Bartel). ARDmyc contains amino acids 1-227 of ARD1 followed bythe same c-myc epitope.
The ARDdra and M -ARD proteins begin with a short segment of lacd(amino acids 318-346, derived from pUB23, provided by A.Varshavsky)followed by the c-myc epitope, with transcription under the control of theGALIO promoter (Guarente etal., 1982) as previously described (Park et al.,1992). This lacI-myc sequence was fused in frame to the N-terminal amino
acids 1 -194 of the ARD1 coding sequence to generate ARDdra, or to the
entire ARDI gene to generate M -ARD.
Wild-type NATI was expressed under the control of the ADH1 promoter
on plasmid pJM 124 (Mullen et al., 1989; provided by R.Sternglanz). Theepitope tagged fluNAT protein begins with the lacd segment described above,followed by a hemagglutinin epitope (Park et al., 1992), followed by the
entire NATI sequence. The epitope tagged NATmyc protein was generatedby PCR (Saiki et al., 1985) modification of NATI and contains the entire
coding sequence of NAT] followed by 11 amino acids (MEQKLISEEDL)of a c-myc epitope (Evans et al., 1985).
Transcriptional activation experiments were done in strains bearing the
multicopy plasmid YEp2l-Sc3423 (Hope and Struhl, 1986; provided byK.Struhl) which carries the lexA operator upstream of a lacZ target gene.
Immunological methods
Cells carrying appropriate plasmids were grown in selective medium (SD
or SD-galactose medium) until they reached exponential growth phase. 10
ml cultures were harvested and resuspended in 500 IAI of SD-met medium
containing 100 ,Ci of [35S]methionine (ICN) and labeled for 20 min at
room temperature with shaking. Cells were harvested and resuspended in
500 M1 of IP buffer (150 mM NaCl, 50 mM Tris 7.5, 5 mM EDTA and
1% Triton X-100) containing protease inhibitors (2 j&g/ml pepstatin A, 10Ag/ml aprotonin, 5 Ag/ml phosphoramidon, 20 /g/ml chymostatin, 5 4g/mlE-64 and 1 mM PMSF). Cells were transferred to Eppendorf tubes containing0.4 ml of chilled glass beads and were disrupted by vortexing for 3 min.
Lysates were centrifuged for 15 min at 12 000 g at 4° C, and the amount
of acid-insoluble 35S in the supernatant was determined. Equal amounts of
total acid-insoluble 35S were processed for immunoprecipitation byincubating with an excess of the indicated antibody for 1 h. The antibodybound proteins were precipitated with Trisacryl -protein A beads (Pierce)and the pellets were washed three times with IP buffer containing 0.1 %SDS. The immunoprecipitates were either analyzed by discontinous PAGE
with subsequent fluorography or assayed for N-terminal acetyltransferase
activity.
Western blot analysis of immunoprecipitates was done by electroblotting
proteins fractionated by SDS-PAGE onto a PVDF membrane (Millipore)in 0.19 M glycine, 0.05 M Tris base, 0.01% SDS and 20% MeOH at 40C.
After transfer, membranes were blocked with 20% FCS in 1 xPBS for 1
h, incubated with appropriate antibodies overnight at 40C, washed andvisualized using alkaline phosphatase-conjugated secondary antibodies(Promega) following the manufacturer's instructions.
Glycerol gradient
Glycerol gradients (10-40%) were prepared by mixing in a gradient mixer5.5 ml of 10% glycerol in IP buffer (without Triton X-100 and with proteaseinhibitors) and 6.2 ml 40% glycerol in the same buffer. Cell extracts were
prepared as for immunoprecipitation and 100 ,ulof each was loaded on top
of each gradient. Samples thus prepared were centrifuged at 200 000 g at
4° C for 35 h, and were collected in -300 A1fractions. As size markers,catalase (236 kDa, Sigma) and aldolase (160 kDa, Sigma) were mixed with
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prepared as for immunoprecipitation and 100 ,ulof each was loaded on top
of each gradient. Samples thus prepared were centrifuged at 200 000 g at
4° C for 35 h, and were collected in -300 A1fractions. As size markers,catalase (236 kDa, Sigma) and aldolase (160 kDa, Sigma) were mixed with
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dimer preparation may actually be due to the presence of
a small amount of ARDi -NAT1 complex.
The idea that ARD1 is a necessary component of the
acetyltransferase is supported by our observation thatimmunoprecipitates obtained from cells overexpressing bothNATmyc and ARDI contain readily detectable enzymeactivity, while immunoprecipitates obtained from cellsoverexpressing only NATmyc do not contain detectable
enzyme activity. The possibility that ARD1 functions tomodify the substrate specificity of NAT1 is not supportedby our experiments with several peptide substrates: theARD1 -NAT1 complex appears to have a qualitatively
similar substrate specificity (unpublished results) to thatreported for the NAT1 dimer (Lee et al., 1988).
The weak sequence similarity of part of the ARD1 protein
to the homeodomain (Whiteway and Szostak, 1985) isprobably not significant. Deletion of a part of this regiondecreases but does not abolish ARDI function. This region
of the ARD1 protein lacks a crucial tryptophan residue foundin all other homeodomains examined so far (Burglin, 1988).
We have presented both genetic and biochemical evidencefor self-association of ARDI. Purification of N-terminal
acetyltransferase activity led to the isolation of dimeric NAT1protein (Lee et al., 1988). Therefore, it is possible that in
the absence of the other subunit, both ARD1 and NAT1 exist
as homodimers. On the other hand, our experiments
demonstrate that N-terminal acetyltransferase activity is a
property of the ARD1-NAT1 complex. If this species is
a heterodimer, it must form in competition with the formation
of the two homodimers. This view is consistent with the fact
that the C-terminal region of the ARD1 protein is requiredfor interaction with both NAT1 and ARD1. Slow exchange
of subunits between homo- and heterodimers would explain
our low recovery of enzyme activity in reconstitutionexperiments involving the mixing of extracts containingoverexpressed ARDI and NAT1.It is suprising that although the ARD1-NAT1 N-terminalacetyltransferase is responsible for the acetylation of a largenumber of proteins (Mullen et al., 1989; Lee et al., 1989b),only a few very specific phenotypes are observed in ardl
or nati mutants. It is likely that the N-terminal acetylationof most proteins is not of great importance, and that onlyin a few critical cases is N-terminal acetylationphysiologically significant. For example, we have shown thatacetylation of the N-terminal serine of histone H4 (Park andSzostak, 1990) or histone H2B (unpublished data) is notrequired, since the N-terminal amino acid can be replacedwithout loss of function by a variety of other amino acidsthat are not acetylated.Further studies on the ARD1-NAT1 N-terminal
acetyltransferase and in particular the identification andcharacterization of the substrates responsible for the ardl
and nati phenotypes will be necessary to unravel the in vivofunctions of N-terminal acetylation.
Materials and methods
Yeast strains and media
The genotypes and sources of S. cerevisiae used in this work are as follows:M107-8B, MATa his3 leu2 ura3 trpl can] ardl::HIS3 (M.Whiteway);M107-6C, MATai his3 leu2 ura3 can] (M.Whiteway); 9-2B, MATa his3leu2 ura3 can] ardl::URA3 (M.Whiteway); 9-3C, MATa his3 leu2 ura3can] (M.Whiteway); W303-la, MATa his3 leu2 ura3 canl(R.Sternglanz);
and AMR7, MATa his3 leu2 ura3 cani natl::URRA3 (R.Sternglanz). SDcontained 0.67% Difco yeast nitrogen base without amino acids, 2% glucose,
and amino acids essential for auxotrophic strains as described by Sherman
et al. (1981). SD-galactose was the same as SD except that galactose was
added instead of glucose.
Plasmids
The chimeric proteins used in this study are diagrammed in Figure 1. Wild-
type ARDI protein and all of the following hybrid proteins wereoverexpressed by placing the corresponding gene under the control of theDEDI promoter (Hope and Struhl, 1986) on a multicopy plasmid. The
lexA-ARD fusion protein was made by fusing the DNA binding domainof lexA (amino acids 1-87, encoded by a HindIII-Xmnnl fragment ofplasmid pRB480 (provided by R.Brent) in frame to the entire ARDI coding
sequence. The related ARD25 protein consists of the same lexA DNAbinding domain fused to seven amino acids (PTLEDPH) derived from a
polylinker sequence, followed by a C-terminal fragment of ARDI (amino
acids 166-238). ARD34 is similar to ARD25 except that the last 11 amino
acids of ARDI (amino acids 228-238) were replaced by a c-myc epitope(DMEQKLISEEDLN) derived from the plasmid pUCmyc (provided byB.Bartel). ARDmyc contains amino acids 1-227 of ARD1 followed bythe same c-myc epitope.
The ARDdra and M -ARD proteins begin with a short segment of lacd(amino acids 318-346, derived from pUB23, provided by A.Varshavsky)followed by the c-myc epitope, with transcription under the control of theGALIO promoter (Guarente etal., 1982) as previously described (Park et al.,1992). This lacI-myc sequence was fused in frame to the N-terminal amino
acids 1 -194 of the ARD1 coding sequence to generate ARDdra, or to the
entire ARDI gene to generate M -ARD.
Wild-type NATI was expressed under the control of the ADH1 promoter
on plasmid pJM 124 (Mullen et al., 1989; provided by R.Sternglanz). Theepitope tagged fluNAT protein begins with the lacd segment described above,followed by a hemagglutinin epitope (Park et al., 1992), followed by the
entire NATI sequence. The epitope tagged NATmyc protein was generatedby PCR (Saiki et al., 1985) modification of NATI and contains the entire
coding sequence of NAT] followed by 11 amino acids (MEQKLISEEDL)of a c-myc epitope (Evans et al., 1985).
Transcriptional activation experiments were done in strains bearing the
multicopy plasmid YEp2l-Sc3423 (Hope and Struhl, 1986; provided byK.Struhl) which carries the lexA operator upstream of a lacZ target gene.
Immunological methods
Cells carrying appropriate plasmids were grown in selective medium (SD
or SD-galactose medium) until they reached exponential growth phase. 10
ml cultures were harvested and resuspended in 500 IAI of SD-met medium
containing 100 ,Ci of [35S]methionine (ICN) and labeled for 20 min at
room temperature with shaking. Cells were harvested and resuspended in
500 M1 of IP buffer (150 mM NaCl, 50 mM Tris 7.5, 5 mM EDTA and
1% Triton X-100) containing protease inhibitors (2 j&g/ml pepstatin A, 10Ag/ml aprotonin, 5 Ag/ml phosphoramidon, 20 /g/ml chymostatin, 5 4g/mlE-64 and 1 mM PMSF). Cells were transferred to Eppendorf tubes containing0.4 ml of chilled glass beads and were disrupted by vortexing for 3 min.
Lysates were centrifuged for 15 min at 12 000 g at 4° C, and the amount
of acid-insoluble 35S in the supernatant was determined. Equal amounts of
total acid-insoluble 35S were processed for immunoprecipitation byincubating with an excess of the indicated antibody for 1 h. The antibodybound proteins were precipitated with Trisacryl -protein A beads (Pierce)and the pellets were washed three times with IP buffer containing 0.1 %SDS. The immunoprecipitates were either analyzed by discontinous PAGE
with subsequent fluorography or assayed for N-terminal acetyltransferase
activity.
Western blot analysis of immunoprecipitates was done by electroblotting
proteins fractionated by SDS-PAGE onto a PVDF membrane (Millipore)in 0.19 M glycine, 0.05 M Tris base, 0.01% SDS and 20% MeOH at 40C.
After transfer, membranes were blocked with 20% FCS in 1 xPBS for 1
h, incubated with appropriate antibodies overnight at 40C, washed andvisualized using alkaline phosphatase-conjugated secondary antibodies(Promega) following the manufacturer's instructions.
Glycerol gradient
Glycerol gradients (10-40%) were prepared by mixing in a gradient mixer5.5 ml of 10% glycerol in IP buffer (without Triton X-100 and with proteaseinhibitors) and 6.2 ml 40% glycerol in the same buffer. Cell extracts were
prepared as for immunoprecipitation and 100 ,ulof each was loaded on top
of each gradient. Samples thus prepared were centrifuged at 200 000 g at
4° C for 35 h, and were collected in -300 A1fractions. As size markers,catalase (236 kDa, Sigma) and aldolase (160 kDa, Sigma) were mixed with
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enzyme activity. The possibility that ARD1 functions tomodify the substrate specificity of NAT1 is not supportedby our experiments with several peptide substrates: theARD1 -NAT1 complex appears to have a qualitatively
similar substrate specificity (unpublished results) to thatreported for the NAT1 dimer (Lee et al., 1988).
The weak sequence similarity of part of the ARD1 protein
to the homeodomain (Whiteway and Szostak, 1985) isprobably not significant. Deletion of a part of this regiondecreases but does not abolish ARDI function. This region
of the ARD1 protein lacks a crucial tryptophan residue foundin all other homeodomains examined so far (Burglin, 1988).
We have presented both genetic and biochemical evidencefor self-association of ARDI. Purification of N-terminal
acetyltransferase activity led to the isolation of dimeric NAT1protein (Lee et al., 1988). Therefore, it is possible that in
the absence of the other subunit, both ARD1 and NAT1 exist
as homodimers. On the other hand, our experiments
demonstrate that N-terminal acetyltransferase activity is a
property of the ARD1-NAT1 complex. If this species is
a heterodimer, it must form in competition with the formation
of the two homodimers. This view is consistent with the fact
that the C-terminal region of the ARD1 protein is requiredfor interaction with both NAT1 and ARD1. Slow exchange
of subunits between homo- and heterodimers would explain
our low recovery of enzyme activity in reconstitutionexperiments involving the mixing of extracts containingoverexpressed ARDI and NAT1.It is suprising that although the ARD1-NAT1 N-terminalacetyltransferase is responsible for the acetylation of a largenumber of proteins (Mullen et al., 1989; Lee et al., 1989b),only a few very specific phenotypes are observed in ardl
or nati mutants. It is likely that the N-terminal acetylationof most proteins is not of great importance, and that onlyin a few critical cases is N-terminal acetylationphysiologically significant. For example, we have shown thatacetylation of the N-terminal serine of histone H4 (Park andSzostak, 1990) or histone H2B (unpublished data) is notrequired, since the N-terminal amino acid can be replacedwithout loss of function by a variety of other amino acidsthat are not acetylated.Further studies on the ARD1-NAT1 N-terminal
acetyltransferase and in particular the identification andcharacterization of the substrates responsible for the ardl
and nati phenotypes will be necessary to unravel the in vivofunctions of N-terminal acetylation.
Materials and methods
Yeast strains and media
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et al. (1981). SD-galactose was the same as SD except that galactose was
added instead of glucose.
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The chimeric proteins used in this study are diagrammed in Figure 1. Wild-
type ARDI protein and all of the following hybrid proteins wereoverexpressed by placing the corresponding gene under the control of theDEDI promoter (Hope and Struhl, 1986) on a multicopy plasmid. The
lexA-ARD fusion protein was made by fusing the DNA binding domainof lexA (amino acids 1-87, encoded by a HindIII-Xmnnl fragment ofplasmid pRB480 (provided by R.Brent) in frame to the entire ARDI coding
sequence. The related ARD25 protein consists of the same lexA DNAbinding domain fused to seven amino acids (PTLEDPH) derived from a
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acids 166-238). ARD34 is similar to ARD25 except that the last 11 amino
acids of ARDI (amino acids 228-238) were replaced by a c-myc epitope(DMEQKLISEEDLN) derived from the plasmid pUCmyc (provided byB.Bartel). ARDmyc contains amino acids 1-227 of ARD1 followed bythe same c-myc epitope.
The ARDdra and M -ARD proteins begin with a short segment of lacd(amino acids 318-346, derived from pUB23, provided by A.Varshavsky)followed by the c-myc epitope, with transcription under the control of theGALIO promoter (Guarente etal., 1982) as previously described (Park et al.,1992). This lacI-myc sequence was fused in frame to the N-terminal amino
acids 1 -194 of the ARD1 coding sequence to generate ARDdra, or to the
entire ARDI gene to generate M -ARD.
Wild-type NATI was expressed under the control of the ADH1 promoter
on plasmid pJM 124 (Mullen et al., 1989; provided by R.Sternglanz). Theepitope tagged fluNAT protein begins with the lacd segment described above,followed by a hemagglutinin epitope (Park et al., 1992), followed by the
entire NATI sequence. The epitope tagged NATmyc protein was generatedby PCR (Saiki et al., 1985) modification of NATI and contains the entire
coding sequence of NAT] followed by 11 amino acids (MEQKLISEEDL)of a c-myc epitope (Evans et al., 1985).
Transcriptional activation experiments were done in strains bearing the
multicopy plasmid YEp2l-Sc3423 (Hope and Struhl, 1986; provided byK.Struhl) which carries the lexA operator upstream of a lacZ target gene.
Immunological methods
Cells carrying appropriate plasmids were grown in selective medium (SD
or SD-galactose medium) until they reached exponential growth phase. 10
ml cultures were harvested and resuspended in 500 IAI of SD-met medium
containing 100 ,Ci of [35S]methionine (ICN) and labeled for 20 min at
room temperature with shaking. Cells were harvested and resuspended in
500 M1 of IP buffer (150 mM NaCl, 50 mM Tris 7.5, 5 mM EDTA and
1% Triton X-100) containing protease inhibitors (2 j&g/ml pepstatin A, 10Ag/ml aprotonin, 5 Ag/ml phosphoramidon, 20 /g/ml chymostatin, 5 4g/mlE-64 and 1 mM PMSF). Cells were transferred to Eppendorf tubes containing0.4 ml of chilled glass beads and were disrupted by vortexing for 3 min.
Lysates were centrifuged for 15 min at 12 000 g at 4° C, and the amount
of acid-insoluble 35S in the supernatant was determined. Equal amounts of
total acid-insoluble 35S were processed for immunoprecipitation byincubating with an excess of the indicated antibody for 1 h. The antibodybound proteins were precipitated with Trisacryl -protein A beads (Pierce)and the pellets were washed three times with IP buffer containing 0.1 %SDS. The immunoprecipitates were either analyzed by discontinous PAGE
with subsequent fluorography or assayed for N-terminal acetyltransferase
activity.
Western blot analysis of immunoprecipitates was done by electroblotting
proteins fractionated by SDS-PAGE onto a PVDF membrane (Millipore)in 0.19 M glycine, 0.05 M Tris base, 0.01% SDS and 20% MeOH at 40C.
After transfer, membranes were blocked with 20% FCS in 1 xPBS for 1
h, incubated with appropriate antibodies overnight at 40C, washed andvisualized using alkaline phosphatase-conjugated secondary antibodies(Promega) following the manufacturer's instructions.
Glycerol gradient
Glycerol gradients (10-40%) were prepared by mixing in a gradient mixer5.5 ml of 10% glycerol in IP buffer (without Triton X-100 and with proteaseinhibitors) and 6.2 ml 40% glycerol in the same buffer. Cell extracts were
prepared as for immunoprecipitation and 100 ,ulof each was loaded on top
of each gradient. Samples thus prepared were centrifuged at 200 000 g at
4° C for 35 h, and were collected in -300 A1fractions. As size markers,catalase (236 kDa, Sigma) and aldolase (160 kDa, Sigma) were mixed with
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acids of ARDI (amino acids 228-238) were replaced by a c-myc epitope(DMEQKLISEEDLN) derived from the plasmid pUCmyc (provided byB.Bartel). ARDmyc contains amino acids 1-227 of ARD1 followed bythe same c-myc epitope.
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Transcriptional activation experiments were done in strains bearing the
multicopy plasmid YEp2l-Sc3423 (Hope and Struhl, 1986; provided byK.Struhl) which carries the lexA operator upstream of a lacZ target gene.
Immunological methods
Cells carrying appropriate plasmids were grown in selective medium (SD
or SD-galactose medium) until they reached exponential growth phase. 10
ml cultures were harvested and resuspended in 500 IAI of SD-met medium
containing 100 ,Ci of [35S]methionine (ICN) and labeled for 20 min at
room temperature with shaking. Cells were harvested and resuspended in
500 M1 of IP buffer (150 mM NaCl, 50 mM Tris 7.5, 5 mM EDTA and
1% Triton X-100) containing protease inhibitors (2 j&g/ml pepstatin A, 10Ag/ml aprotonin, 5 Ag/ml phosphoramidon, 20 /g/ml chymostatin, 5 4g/mlE-64 and 1 mM PMSF). Cells were transferred to Eppendorf tubes containing0.4 ml of chilled glass beads and were disrupted by vortexing for 3 min.
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of acid-insoluble 35S in the supernatant was determined. Equal amounts of
total acid-insoluble 35S were processed for immunoprecipitation byincubating with an excess of the indicated antibody for 1 h. The antibodybound proteins were precipitated with Trisacryl -protein A beads (Pierce)and the pellets were washed three times with IP buffer containing 0.1 %SDS. The immunoprecipitates were either analyzed by discontinous PAGE
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After transfer, membranes were blocked with 20% FCS in 1 xPBS for 1
h, incubated with appropriate antibodies overnight at 40C, washed andvisualized using alkaline phosphatase-conjugated secondary antibodies(Promega) following the manufacturer's instructions.
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Glycerol gradients (10-40%) were prepared by mixing in a gradient mixer5.5 ml of 10% glycerol in IP buffer (without Triton X-100 and with proteaseinhibitors) and 6.2 ml 40% glycerol in the same buffer. Cell extracts were
prepared as for immunoprecipitation and 100 ,ulof each was loaded on top
of each gradient. Samples thus prepared were centrifuged at 200 000 g at
4° C for 35 h, and were collected in -300 A1fractions. As size markers,catalase (236 kDa, Sigma) and aldolase (160 kDa, Sigma) were mixed with
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samples prior to loading onto gradients. Fractions 10- 14 from the bottom
of the gradient were assayed for catalase and fractions 15 -22 for aldolase,
following instructions provided by the manufacturer. Every fraction was
subjected to immunoprecipitation using anti-myc antibody as described above.
N-terminal acetyltransferase assay
The enzyme assay was carried out on immunoprecipitates as described (Lee
et al., 1988) with minor modifications. We only assayed immunoprecipitates
since crude extracts contain other acetyltranferase activities and non-specific
hydrolases that interfere with the assay. An assay mixture contains the
enzyme (immunoprecipitate), 20 jiM ACTH (1-24) and 6.8 1M [3H]acetylCoA (3.18 Ci/mmol, Amersham) in 75 mM Tris pH 8.2, 150 mM NaCl,
0.1 mM EDTA and 2 mM ,3-mercaptoethanol. The assay mixture was
incubated for 1 h at room temperature. The enzyme activities were measured
by counting the amount of radioactivity present in ACTH after collecting
the substrate on glass fiber filters.
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Fig. 1. Schematic diagram of ARDI and NATI derived constructs. Arrows pointing up indicate the location of the stretch of negatively charged
amino acids; arrows pointing down indicate the region of the ARDI protein with sequence similarity to the homeodomain. LexA is the lexA DNA
binding domain; myc represents the epitope recognized by the monoclonal antibody 9E10 (Evans et al., 1985); flu is the epitope recognized by the
monoclonal antibody 12CA5 (Field et al., 1988); and lacd represents a segment of the lacI gene (Park and Szostak, 1992).
hemagglutinin (HA) protein of influenza virus (Field et al.,
1988) to generate the fluNAT fusion protein illustrated in
Figure 1. The ARDM protein was tagged with the myc
epitope as before (ARDmyc). Extracts prepared from cells
overexpressing both ARDmyc and fluNAT were
immunoprecipitated either with the anti-myc antibody or with
an anti-HA antibody (Figure 2B). The anti-myc antibody
immunoprecipitated ARDmyc and an additional protein of
97 kDa, the size of NAT1. The anti-HA antibody
immunoprecipitated the fluNAT fusion protein and an
additional protein that comigrated with the ARDmyc protein,
confirming that the ARDI protein forms a complex with the
NATI protein.
ARD 1 protein can form homodimers
The ARDI protein contains a stretch of negatively charged
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type ARD1 protein, and that this heterodimer is able to
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To test this hypothesis, we examined the physical inter-
actions between two forms of ARD1 protein (ARDmyc and
lexA -ARD) that can be distinguished immunologically and
by size. The ARDmyc fusion protein is immunoprecipitated
by an anti-myc antibody and is approximately the same size
as the wild-type protein (Figure 3A, lane b). The lexA-ARD











97- ( 1 N XTI
68 4_ _I <-- 1 t.l- \ -x T
6843 -- -
- 2 A Rl Dnvc
_ -. 3 ARIDdra
43
w -- -.4 2
2b





* .-\ 11 t - 11d,,,i -r,:4'.' X 4 AT'. -_11 e .1 1T U
Fig. 2. Co-immunoprecipitation of ARDI and NATI proteins. (A) Derivatives of strain 9-3C overexpressing ARDmyc (lane a), NATI and ARDmyc
(lane b), NATI and ARD34 (lane c), NATI and ARDdra (lane d) and NATI (lane e) were labeled with [35S]methionine. Extracts made from these
cultures were immunoprecipitated with the anti-myc monoclonal antibody. The immunoprecipitates were analyzed on 15% SDS-PAGE and subjected
to fluorography. Band corresponds to NATI, band 2 to ARDmyc, band 3 to ARDdra and band 4 to ARD34. More immunoprecipitate was loaded
in lanes d and e than in lanes a, b and c (compare intensities of 43 kDa background band). (B) Derivatives of strain W303-la overexpressing either
ARDmyc (lane a), fluNAT (lane b), or both ARDmyc and fluNAT (lanes c and d), were labeled with [35S]methionine. Extracts made from these
cultures were immunoprecipitated with the anti-myc monoclonal antibody (lanes a-c) or the anti-hemagglutinin monoclonal antibody (lane d). The
immunoprecipitates were fractionated by 15% SDS-PAGE and subjected to fluorography. Band corresponds to fluNAT, and band 2 to ARDmyc.
Plasmids used to overproduce the proteins indicated are shown in Figure 1.
and is larger than the wild-type protein (Figure 3A, lane a).
When an extract made from cells overexpressing both the
ARDmyc and the lex-ARD fusions was treated with the anti-
myc antibody, both the ARDmyc fusion protein and a more
slowly migrating protein were immunoprecipitated
(Figure 3A, lane c). The latter protein comigrated with the
lexA -ARD fusion protein. We confirmed the identity of this
protein by Western blot analysis of the immunoprecipitates
(Figure 3B). The same immunoprecipitates as shown in
Figure 3A were fractionated by SDS -PAGE, and blotted
onto a membrane. A part of the membrane was probed with
an anti-myc antibody and another part with anti-ARDl
antisera. As controls, immunoprecipitates obtained with an
anti-myc antibody from cells overexpressing either the
untagged ARD1 protein only (lane a) or the ARDmyc protein
only (lane d) were probed with an anti-myc antibody, and
immunoprecipitates obtained with anti-ARDl antisera from
cells overexpressing lexA -ARD only were probed with anti-
ARDI antisera (lane g). As expected, the anti-myc antibody
recognizes the ARDmyc protein (lane c). However, the anti-
ARDI antiserum recognized an additional band (lane f) which
has the same mobility as lexA -ARD (lane g), showing that
the slower migrating band is lexA -ARD. Parallel experi-
ments done with the N-terminally deleted and c-myc epitope
tagged lexA -ARD fusion (ARD34) show that the N-tenninal
region of ARDI is not required for this interaction (lanes b
and e). These experiments confirm the initial genetic data and
show that the ARDI protein has the potential to form
homodimers through its C-terminal region.
ARD1 interacts with NAT1 through its C-terminal
region
To localize the NAT 1 interaction site in the ARD 1 protein,
we looked for co-immunoprecipitation of NAT1 with
truncated derivatives of the ARDmyc fusion protein. The
Table I. ,3-galactosidase activities induced by lexA fusion proteins






A unit is defined by 0D420 x 1000/(min)(0D600)(rnl). Strains used for
the experiment are M107-6B (ARD1) and M107-8B (ard 1). The lacZ
gene was placed downstream of a lexA operator and carried on
plasmid YEp21-Sc3423 (Hope and Struhl, 1986). Plasniids expressing
the lexA fusion proteins are shown in Figure 1.
ARD34 construct contains only the C-terminal portion of
ARD1 (amino acids 166-227), and is capable of forming
heterodimers with intact ARD1. This protein is also capable
of forming heterodimers with NAT1, by the criterion of co-
immunoprecipitation (lane c, Figure 2A). The converse
construct, ARDdra, which contains the N-terminal region
of the ARDI protein (amino acids 1-194) co-
immunoprecipitated little if any NATI (lane d, Figure 2A),
although it did complement an ardl null mutation (9-2B)
when overexpressed from a GALIO promoter. One possible
explanation for this result is that this protein can still interact
weakly with NAT 1, such that at high protein levels enough
functional complex is formed to complement. Alternatively,
the C-terminally truncated protein could simply be unstable.
We tested the latter possibility by a pulse -chase experiment
(Figure 4). There is no obvious difference in the stability
of the full-length (band 1) and truncated proteins (band 2),
supporting the notion that the primary interaction domain
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Fig. 2. Co-immunoprecipitation of ARDI and NATI proteins. (A) Derivatives of strain 9-3C overexpressing ARDmyc (lane a), NATI and ARDmyc
(lane b), NATI and ARD34 (lane c), NATI and ARDdra (lane d) and NATI (lane e) were labeled with [35S]methionine. Extracts made from these
cultures were immunoprecipitated with the anti-myc monoclonal antibody. The immunoprecipitates were analyzed on 15% SDS-PAGE and subjected
to fluorography. Band corresponds to NATI, band 2 to ARDmyc, band 3 to ARDdra and band 4 to ARD34. More immunoprecipitate was loaded
in lanes d and e than in lanes a, b and c (compare intensities of 43 kDa background band). (B) Derivatives of strain W303-la overexpressing either
ARDmyc (lane a), fluNAT (lane b), or both ARDmyc and fluNAT (lanes c and d), were labeled with [35S]methionine. Extracts made from these
cultures were immunoprecipitated with the anti-myc monoclonal antibody (lanes a-c) or the anti-hemagglutinin monoclonal antibody (lane d). The
immunoprecipitates were fractionated by 15% SDS-PAGE and subjected to fluorography. Band corresponds to fluNAT, and band 2 to ARDmyc.
Plasmids used to overproduce the proteins indicated are shown in Figure 1.
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Fig. 3. Formation of ARDI dimers. (A) Co-immunoprecipitation of two forms of ARD1. Derivatives of strain 9-3C overexpressing lexA-ARD(lane a), ARDmyc (lane b), lexA-ARD and ARDmyc (lane c), and wild-type ARDI (lane d) were labeled with [35S]methionine. Extracts madefrom these cells were immunoprecipitated with either anti-ARD1 antisera (lane a) or anti-myc monoclonal antibody (lanes b-d). (B) Western blotanalysis of immunoprecipitates. Derivatives of strain 9-3C overexpressing ARD1 (lane a), lexA-ARD and ARD34 (lanes b and e), lexA-ARD andARDmyc (lanes c and f), ARDmyc (lane d), or lexA-ARD (lane g) were labeled with [35S]methionine. Extracts made from these cultures wereimmunoprecipitated with either the anti-myc monoclonal antibody (lanes a-f) or anti-ARDl antisera (lane g). The precipitates were fractionated by15% SDS-PAGE, blotted onto PVDF membrane, and probed with either the anti-myc antibody (lanes a-c) or anti-ARDl antibody (lanes d-g).Plasmids used to overproduce the proteins indicated are shown in Figure 1.
Both ARD1 and NATl proteins are required for the N-
terminal acetyltransferase activity
Having established that the ARDI and NATI proteins form
a complex, we next determined whether both proteins are
required for the N-terminal acetyltransferase activity. To
address this question, we used myc epitope tagged derivatives
of ARDI and NATI, and purified ARDmyc, NATmyc,
ARDmyc -NAT 1 or ARD 1- NATmyc proteins by
immunoprecipitation using the anti-myc antibody. The
immunoprecipitates were then assayed for their ability to
catalyze acetylation of a peptide substrate, ACTH (1-24)
(Lee et al., 1988). In this assay, we measured the amount
of radioactivity that was transferred from [3H]acetyl CoA
to ACTH (1-24). As shown in Table II, the immuno-
precipitate obtained from cells overexpressing both ARDmyc
and NATI (extract A) was able to catalyze the N-terminal
acetyltransferase reaction efficiently. Extract B (ARDI and
NATmyc) immunoprecipitates were considerably less active
than extract A immunoprecipitates, possibly because the
NATmyc protein is less efficiently immunoprecipitated than
ARDmyc. Immunoprecipitates obtained from cells over-
expressing only non-tagged NAT1, only ARDmyc or only
NATmyc (extracts E, C and D, respectively) did not show
detectable enzyme activity.
We have been able to reconstitute at least a small amount
of enzyme activity by mixing two inactive extracts (extracts
C and E), one containing overexpressed ARDmyc and the
other containing overexpressed NAT 1. The two extracts
were mixed and incubated at 0° C for 15-60 min, and then
immunoprecipitated and assayed. It is clear that only a small
fraction of the potential activity is reconstituted. Longer
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Fig. 4. Comparison of stabilities of M-ARD and ARDdra.Derivatives of strain (9-3C) expressing M-ARD (lanes a-d), orARDdra (lanes e-h) were pulse-labeled for 5 min and chased for 0(lanes a and e), 10 (lanes b and f), 30 (lanes c and g) and 60 (lanes dand h) min. Band 1 corresponds to M-ARD and band 2 to ARDdra.Plasmids used to overproduce the proteins indicated are shown inFigure 1.
incubation times or incubation at higher temperatures (30° C)did not lead to the recovery of more activity, suggesting that
most of the ARDmyc and NAT1 protein is sequestered in
an inaccessible form.
Detection of the ARD 1 -NAT1 complex on glycerolgradients
We used glycerol gradients to fractionate cell extracts made
from strains overproducing ARDmyc alone (Figure 5A) orboth ARDmyc and NAT1 (Figure 5B) to determine the
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Fig. 3. Formation of ARDI dimers. (A) Co-immunoprecipitation of two forms of ARD1. Derivatives of strain 9-3C overexpressing lexA-ARD(lane a), ARDmyc (lane b), lexA-ARD and ARDmyc (lane c), and wild-type ARDI (lane d) were labeled with [35S]methionine. Extracts madefrom these cells were immunoprecipitated with either anti-ARD1 antisera (lane a) or anti-myc monoclonal antibody (lanes b-d). (B) Western blotanalysis of immunoprecipitates. Derivatives of strain 9-3C overexpressing ARD1 (lane a), lexA-ARD and ARD34 (lanes b and e), lexA-ARD andARDmyc (lanes c and f), ARDmyc (lane d), or lexA-ARD (lane g) were labeled with [35S]methionine. Extracts made from these cultures wereimmunoprecipitated with either the anti-myc monoclonal antibody (lanes a-f) or anti-ARDl antisera (lane g). The precipitates were fractionated by15% SDS-PAGE, blotted onto PVDF membrane, and probed with either the anti-myc antibody (lanes a-c) or anti-ARDl antibody (lanes d-g).Plasmids used to overproduce the proteins indicated are shown in Figure 1.
Both ARD1 and NATl proteins are required for the N-
terminal acetyltransferase activity
Having established that the ARDI and NATI proteins form
a complex, we next determined whether both proteins are
required for the N-terminal acetyltransferase activity. To
address this question, we used myc epitope tagged derivatives
of ARDI and NATI, and purified ARDmyc, NATmyc,
ARDmyc -NAT 1 or ARD 1- NATmyc proteins by
immunoprecipitation using the anti-myc antibody. The
immunoprecipitates were then assayed for their ability to
catalyze acetylation of a peptide substrate, ACTH (1-24)
(Lee et al., 1988). In this assay, we measured the amount
of radioactivity that was transferred from [3H]acetyl CoA
to ACTH (1-24). As shown in Table II, the immuno-
precipitate obtained from cells overexpressing both ARDmyc
and NATI (extract A) was able to catalyze the N-terminal
acetyltransferase reaction efficiently. Extract B (ARDI and
NATmyc) immunoprecipitates were considerably less active
than extract A immunoprecipitates, possibly because the
NATmyc protein is less efficiently immunoprecipitated than
ARDmyc. Immunoprecipitates obtained from cells over-
expressing only non-tagged NAT1, only ARDmyc or only
NATmyc (extracts E, C and D, respectively) did not show
detectable enzyme activity.
We have been able to reconstitute at least a small amount
of enzyme activity by mixing two inactive extracts (extracts
C and E), one containing overexpressed ARDmyc and the
other containing overexpressed NAT 1. The two extracts
were mixed and incubated at 0° C for 15-60 min, and then
immunoprecipitated and assayed. It is clear that only a small
fraction of the potential activity is reconstituted. Longer
2090









Fig. 4. Comparison of stabilities of M-ARD and ARDdra.Derivatives of strain (9-3C) expressing M-ARD (lanes a-d), orARDdra (lanes e-h) were pulse-labeled for 5 min and chased for 0(lanes a and e), 10 (lanes b and f), 30 (lanes c and g) and 60 (lanes dand h) min. Band 1 corresponds to M-ARD and band 2 to ARDdra.Plasmids used to overproduce the proteins indicated are shown inFigure 1.
incubation times or incubation at higher temperatures (30° C)did not lead to the recovery of more activity, suggesting that
most of the ARDmyc and NAT1 protein is sequestered in
an inaccessible form.
Detection of the ARD 1 -NAT1 complex on glycerolgradients
We used glycerol gradients to fractionate cell extracts made
from strains overproducing ARDmyc alone (Figure 5A) orboth ARDmyc and NAT1 (Figure 5B) to determine the
13






-- --f- ;::7 ;.-:r, - Z;z - -, - -
T71 C!. :.7
1- I -I!,r- I 'Z 4.'
-4 An ti- III%, c --*. .4 A iiti -A IZ D I -- 10-
Table II. N-terminal acetyltransferase activities
Strain Overexpressed Extract Activity in
genotype protein(s) immunoprecipitate
(k.c.p.m.)
WT ARDmyc + NATI A 1700-10 000
WT ARDI + NATmyc B 17-106
tiatl ARDmyc C <1
ardl NATmyc D < 1
WT NATI E <1
C+E 13-112
In all cases, immunoprecipitates were obtained by using an anti-myc
antibody. Equal fractions of immunoprecipitates obtained from 8 ml
cultures were assayed for N-terminal acetyltransferase activity as
described in Materials and methods. WT, W303-la; nati, AMR7 and
ardl, 9-2B.
composition of the ARD1-NATI complex. Every fraction
from a gradient was immunoprecipitated with the anti-myc
antibody. Odd-numbered fractions were analyzed by
SDS -PAGE and even-numbered fractions were assayed for
N-terminal acetyltransferase activity. The strain
overproducing only ARDmyc showed a single peak of
ARDmyc protein centered at fractions 25 and 27
(Figure 5A), near the top of the gradient. In contrast, the
ARDmyc protein from cells overproducing both ARDmyc
and NATI was detected not only in this peak but also in
an additional peak at fractions 19 and 21, corresponding to
a molecular weight somewhat less than that of aldolase (160
kDa). These fractions contained an additional protein of 97
kDa, the expected size of NAT1. N-terminal acetyltrans-
ferase activity was found only in the gradient containing both
ARDmyc and NAT1, and enzyme activity was detected in
fractions 18 and 20, corresponding to the fractions containing
the ARDmyc -NAT1 complex. The estimated size of the
active complex and the relative intensity of the NAT1 and
ARDmyc bands are consistent with either a single ARD1
molecule or an ARDI dimer forming a complex with a single
NATI molecule. These experiments confirm that the ARD1
protein is a subunit of the N-terminal acetyltransferase.
A












The similar phenotypes of ardl and nat] mutants first
suggested that they are involved in the same pathway (Mullen
et al., 1989; Lee et al., 1989a). Because overexpression of
both gene products is required for the overproduction of
enzyme activity, Mullen et al. (1989) also suggested that the
ARD1 and NAT1 proteins are subunits of the enzyme
complex. In this report we have presented biochemical
evidence showing that the ARD1 and NAT1 proteins interact
physically, and that the ARD1-NAT1 complex constitutes
an N-terminal protein acetyltransferase.
Purification of N-terminal acetyltransferase activity using
a peptide acetylation assay resulted in the isolation of a
protein that appeared to be a dimer of NAT1 alone (Lee
et al., 1988). The possibility that NAT1 by itself had
acetyltransferase activity was consistent with the limited
sequence similarity of this protein with chloramphenicol
acetyltransferase (Mullen et al., 1989). However, the
specific activity of the apparently homogeneous NAT1 dimer
( 8000 U/mg of NAT1: Lee et al., 1988) appears to be
substantially lower than that of the ARDmyc -NAT 1
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Fig. 5. Glycerol gradient fractionation of cell extracts. Derivatives of
strains (9-3C) overexpressing ARDmyc alone (A) or ARDmyc and
NATI (B) were labeled with [35S]methionine. Extracts made from
these cells were separated on 10-40% glycerol gradients. Odd-
numbered fractions were immunoprecipitated with anti-myc antibody
and analyzed by 15% SDS-PAGE. Band 1 corresponds to ARDmyc
and band 2 to NAT1. Positions of molecular weight markers, catalase
(236 kDa) and aldolase (160 kDa), are shown. Even-numbered
fractions were used for N-terminal acetyltransferase assays (shown
above gel B) after immunoprecipitation with anti-myc antibody.
complex we obtained (>3 000 000 U/mg of NAT 1; this
is a rough estimate based upon the amount of NATI observed
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tiatl ARDmyc C <1
ardl NATmyc D < 1
WT NATI E <1
C+E 13-112
In all cases, immunoprecipitates were obtained by using an anti-myc
antibody. Equal fractions of immunoprecipitates obtained from 8 ml
cultures were assayed for N-terminal acetyltransferase activity as
described in Materials and methods. WT, W303-la; nati, AMR7 and
ardl, 9-2B.
composition of the ARD1-NATI complex. Every fraction
from a gradient was immunoprecipitated with the anti-myc
antibody. Odd-numbered fractions were analyzed by
SDS -PAGE and even-numbered fractions were assayed for
N-terminal acetyltransferase activity. The strain
overproducing only ARDmyc showed a single peak of
ARDmyc protein centered at fractions 25 and 27
(Figure 5A), near the top of the gradient. In contrast, the
ARDmyc protein from cells overproducing both ARDmyc
and NATI was detected not only in this peak but also in
an additional peak at fractions 19 and 21, corresponding to
a molecular weight somewhat less than that of aldolase (160
kDa). These fractions contained an additional protein of 97
kDa, the expected size of NAT1. N-terminal acetyltrans-
ferase activity was found only in the gradient containing both
ARDmyc and NAT1, and enzyme activity was detected in
fractions 18 and 20, corresponding to the fractions containing
the ARDmyc -NAT1 complex. The estimated size of the
active complex and the relative intensity of the NAT1 and
ARDmyc bands are consistent with either a single ARD1
molecule or an ARDI dimer forming a complex with a single
NATI molecule. These experiments confirm that the ARD1
protein is a subunit of the N-terminal acetyltransferase.
A












The similar phenotypes of ardl and nat] mutants first
suggested that they are involved in the same pathway (Mullen
et al., 1989; Lee et al., 1989a). Because overexpression of
both gene products is required for the overproduction of
enzyme activity, Mullen et al. (1989) also suggested that the
ARD1 and NAT1 proteins are subunits of the enzyme
complex. In this report we have presented biochemical
evidence showing that the ARD1 and NAT1 proteins interact
physically, and that the ARD1-NAT1 complex constitutes
an N-terminal protein acetyltransferase.
Purification of N-terminal acetyltransferase activity using
a peptide acetylation assay resulted in the isolation of a
protein that appeared to be a dimer of NAT1 alone (Lee
et al., 1988). The possibility that NAT1 by itself had
acetyltransferase activity was consistent with the limited
sequence similarity of this protein with chloramphenicol
acetyltransferase (Mullen et al., 1989). However, the
specific activity of the apparently homogeneous NAT1 dimer
( 8000 U/mg of NAT1: Lee et al., 1988) appears to be
substantially lower than that of the ARDmyc -NAT 1
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Fig. 5. Glycerol gradient fractionation of cell extracts. Derivatives of
strains (9-3C) overexpressing ARDmyc alone (A) or ARDmyc and
NATI (B) were labeled with [35S]methionine. Extracts made from
these cells were separated on 10-40% glycerol gradients. Odd-
numbered fractions were immunoprecipitated with anti-myc antibody
and analyzed by 15% SDS-PAGE. Band 1 corresponds to ARDmyc
and band 2 to NAT1. Positions of molecular weight markers, catalase
(236 kDa) and aldolase (160 kDa), are shown. Even-numbered
fractions were used for N-terminal acetyltransferase assays (shown
above gel B) after immunoprecipitation with anti-myc antibody.
complex we obtained (>3 000 000 U/mg of NAT 1; this
is a rough estimate based upon the amount of NATI observed
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